A PHASE 2, 12-WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06730512 FOLLOWING MULTIPLE DOSES IN ADULT SUBJECTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2019
At a glance
- Drugs PF-06730512 (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Therapeutic Use
- Sponsors Pfizer
- 06 Nov 2018 Planned End Date changed from 30 Jun 2021 to 12 Jul 2021.
- 06 Nov 2018 Planned primary completion date changed from 30 Jun 2021 to 12 Jul 2021.
- 18 Sep 2018 Planned End Date changed from 7 May 2021 to 30 Jun 2021.